Leonteq Securities AG Acquires Shares of 195,000 Iovance Biotherapeutics, Inc. $IOVA

Leonteq Securities AG purchased a new stake in shares of Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm purchased 195,000 shares of the biotechnology company’s stock, valued at approximately $532,000.

Several other institutional investors and hedge funds have also recently modified their holdings of IOVA. Royal Bank of Canada increased its holdings in shares of Iovance Biotherapeutics by 161.2% during the first quarter. Royal Bank of Canada now owns 522,887 shares of the biotechnology company’s stock valued at $1,740,000 after acquiring an additional 322,680 shares in the last quarter. AQR Capital Management LLC increased its holdings in shares of Iovance Biotherapeutics by 279.0% during the first quarter. AQR Capital Management LLC now owns 59,540 shares of the biotechnology company’s stock valued at $195,000 after acquiring an additional 43,829 shares in the last quarter. Goldman Sachs Group Inc. increased its holdings in shares of Iovance Biotherapeutics by 30.5% during the first quarter. Goldman Sachs Group Inc. now owns 5,571,902 shares of the biotechnology company’s stock valued at $18,554,000 after acquiring an additional 1,301,846 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its holdings in shares of Iovance Biotherapeutics by 202.8% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 5,777,344 shares of the biotechnology company’s stock valued at $19,239,000 after acquiring an additional 3,869,617 shares in the last quarter. Finally, Envestnet Asset Management Inc. increased its holdings in shares of Iovance Biotherapeutics by 112.1% during the second quarter. Envestnet Asset Management Inc. now owns 47,466 shares of the biotechnology company’s stock valued at $82,000 after acquiring an additional 25,083 shares in the last quarter. 77.03% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

IOVA has been the subject of several analyst reports. Weiss Ratings restated a “sell (d-)” rating on shares of Iovance Biotherapeutics in a report on Monday, April 6th. Wall Street Zen upgraded Iovance Biotherapeutics from a “sell” rating to a “hold” rating in a report on Saturday, February 28th. Barclays raised their price target on Iovance Biotherapeutics from $10.00 to $11.00 and gave the company an “overweight” rating in a report on Wednesday, February 25th. Truist Financial upgraded Iovance Biotherapeutics to a “hold” rating in a report on Wednesday, March 25th. Finally, The Goldman Sachs Group reiterated a “sell” rating and issued a $2.00 price objective on shares of Iovance Biotherapeutics in a report on Thursday, February 5th. Five equities research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and two have issued a Sell rating to the company. According to data from MarketBeat.com, the company has an average rating of “Hold” and an average target price of $8.43.

Iovance Biotherapeutics Stock Up 11.1%

Iovance Biotherapeutics stock opened at $4.11 on Friday. The business has a 50-day simple moving average of $3.63 and a two-hundred day simple moving average of $3.04. The company has a market cap of $1.84 billion, a P/E ratio of -4.33 and a beta of 0.69. Iovance Biotherapeutics, Inc. has a 52-week low of $1.66 and a 52-week high of $5.63.

Iovance Biotherapeutics (NASDAQ:IOVA) last released its quarterly earnings results on Thursday, May 7th. The biotechnology company reported ($0.19) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.19). The business had revenue of $71.43 million during the quarter, compared to the consensus estimate of $77.84 million. Iovance Biotherapeutics had a negative return on equity of 50.17% and a negative net margin of 123.92%.The business’s quarterly revenue was up 44.9% compared to the same quarter last year. During the same period in the previous year, the company posted ($0.36) EPS. Research analysts anticipate that Iovance Biotherapeutics, Inc. will post -0.6 EPS for the current fiscal year.

Iovance Biotherapeutics Company Profile

Iovance Biotherapeutics, Inc is a clinical?stage biotechnology company specializing in the development and commercialization of tumor?infiltrating lymphocyte (TIL) immunotherapies for the treatment of solid tumors. The company’s lead product candidate, lifileucel (formerly LN?144), is an autologous TIL therapy in late?stage clinical development for patients with advanced melanoma. Iovance’s pipeline also includes next?generation TIL programs such as LN?145 for cervical and other human papillomavirus (HPV)?related cancers, as well as exploratory studies in head and neck, non?small cell lung, gastric and other solid tumor indications.

Iovance’s TIL platform harnesses a patient’s own immune system by isolating, expanding and reinfusing tumor?reactive lymphocytes.